| Drug Name: | Dapagliflozin |
|---|
| Drug Class: | Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
|---|
| Mechanism of Action: | - Inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion
- Results in decreased blood glucose levels and weight loss
|
|---|
| Use: | - Type 2 diabetes mellitus
- Reduction of cardiovascular death and hospitalization for heart failure in patients with heart failure and reduced ejection fraction
|
|---|
| Side Effects: | - Genital mycotic infections
- Urinary tract infections
- Increased urination
- Hypotension
- Dehydration
- Increased LDL cholesterol
- Increased risk of bone fractures
|
|---|
| Contraindications: | - Severe renal impairment
- End-stage renal disease
- Hypersensitivity to dapagliflozin
|
|---|
| Specialty: | |
|---|